TherapeuticsMD Inc (TXMD) Upgraded at Zacks Investment Research

TherapeuticsMD Inc (TXMD) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of TherapeuticsMD Inc (NASDAQ:TXMD) from a sell rating to a hold rating in a research note published on Tuesday morning.

According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “

A number of other equities research analysts have also weighed in on the stock. Oppenheimer Holdings, Inc. reaffirmed an outperform rating and set a $12.00 price target on shares of TherapeuticsMD in a report on Wednesday, December 7th. Jefferies Group LLC set a $18.00 price target on shares of TherapeuticsMD and gave the company a buy rating in a report on Tuesday, December 6th. Stifel Nicolaus raised their price target on shares of TherapeuticsMD from $14.00 to $17.00 and gave the company a buy rating in a report on Tuesday, December 6th. Guggenheim reaffirmed a positive rating on shares of TherapeuticsMD in a report on Tuesday, December 6th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a buy rating and set a $10.50 price target on shares of TherapeuticsMD in a report on Sunday, December 4th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $14.38.

TherapeuticsMD (NASDAQ:TXMD) traded down 0.35% during midday trading on Tuesday, hitting $5.75. 215,222 shares of the stock traded hands. TherapeuticsMD has a one year low of $4.39 and a one year high of $9.29. The company’s market cap is $1.13 billion. The company’s 50-day moving average is $5.86 and its 200-day moving average is $6.58.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its position in shares of TherapeuticsMD by 8.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,465,462 shares of the company’s stock valued at $159,800,000 after buying an additional 1,798,290 shares in the last quarter. BlackRock Fund Advisors raised its position in shares of TherapeuticsMD by 9.2% in the third quarter. BlackRock Fund Advisors now owns 5,059,418 shares of the company’s stock valued at $34,455,000 after buying an additional 426,991 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of TherapeuticsMD by 8.3% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 4,005,977 shares of the company’s stock valued at $27,281,000 after buying an additional 308,027 shares in the last quarter. Rock Springs Capital Management LP raised its position in shares of TherapeuticsMD by 14.3% in the third quarter. Rock Springs Capital Management LP now owns 1,800,000 shares of the company’s stock valued at $12,258,000 after buying an additional 225,000 shares in the last quarter. Finally, Northern Trust Corp raised its position in shares of TherapeuticsMD by 0.6% in the third quarter. Northern Trust Corp now owns 1,745,816 shares of the company’s stock valued at $11,888,000 after buying an additional 9,720 shares in the last quarter.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare product company. The Company’s segment is creating and commercializing products for women. It is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. Its drug candidates are created using its SYMBODA hormone technology, which enables the administration of hormones with high bioavailability alone or in combination.

Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment